Esperion Therapeutics Stock Buy Hold or Sell Recommendation

ESPR Stock  USD 2.54  0.03  1.17%   
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Esperion Therapeutics is 'Strong Hold'. A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Esperion Therapeutics given historical horizon and risk tolerance towards Esperion Therapeutics. When Macroaxis issues a 'buy' or 'sell' recommendation for Esperion Therapeutics, the advice is generated through an automated system that utilizes algorithms and statistical models.
  
Check out Esperion Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool.
To learn how to invest in Esperion Stock, please use our How to Invest in Esperion Therapeutics guide.
Note, we conduct extensive research on individual companies such as Esperion and provide practical buy, sell, or hold advice based on investors' constraints. Esperion Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

Execute Esperion Therapeutics Buy or Sell Advice

The Esperion recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Esperion Therapeutics. Macroaxis does not own or have any residual interests in Esperion Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Esperion Therapeutics' advice using the current market data and latest reported fundamentals.

Time Horizon

Risk Tolerance

Execute Advice
Sell Esperion TherapeuticsBuy Esperion Therapeutics
Strong Hold

Market Performance

OKDetails

Volatility

Relatively riskyDetails

Hype Condition

Under hypedDetails

Current Valuation

UndervaluedDetails

Odds Of Distress

Quite HighDetails

Economic Sensitivity

Actively responds to the marketDetails

Investor Sentiment

AlarmedDetails

Analyst Consensus

BuyDetails

Financial Strenth (F Score)

Very WeakDetails

Financial Leverage

Not RatedDetails

Reporting Quality (M-Score)

Unlikely ManipulatorDetails
For the selected time horizon Esperion Therapeutics has a Risk Adjusted Performance of 0.1265, Jensen Alpha of 0.4644, Total Risk Alpha of 0.0069, Sortino Ratio of 0.1427 and Treynor Ratio of 0.3522
We provide trade advice to complement the prevailing expert consensus on Esperion Therapeutics. Our dynamic recommendation engine uses a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at the time. To make sure Esperion Therapeutics is not overpriced, please confirm all Esperion Therapeutics fundamentals, including its total debt, and the relationship between the revenue and price to earnings to growth . Please also check Esperion Therapeutics number of shares shorted to verify your buy or sell decision is consistent with all fundamental data available and that the company can sustain itself in the current economic cycle.

Esperion Therapeutics Trading Alerts and Improvement Suggestions

Esperion Therapeutics appears to be risky and price may revert if volatility continues
Esperion Therapeutics has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 116.33 M. Net Loss for the year was (209.25 M) with loss before overhead, payroll, taxes, and interest of (70.42 M).
Esperion Therapeutics currently holds about 185.84 M in cash with (135.49 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.79, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Esperion Therapeutics has a very weak financial position based on the latest SEC disclosures
Roughly 66.0% of the company shares are held by institutions such as insurance companies
Latest headline from gurufocus.com: Otsuka Submits New Drug Application in Japan for Bempedoic Acid in the Treatment of ...

Esperion Therapeutics Returns Distribution Density

The distribution of Esperion Therapeutics' historical returns is an attempt to chart the uncertainty of Esperion Therapeutics' future price movements. The chart of the probability distribution of Esperion Therapeutics daily returns describes the distribution of returns around its average expected value. We use Esperion Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Esperion Therapeutics returns is essential to provide solid investment advice for Esperion Therapeutics.
Mean Return
0.70
Value At Risk
-5.83
Potential Upside
10.20
Standard Deviation
4.54
   Return Density   
       Distribution  
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Esperion Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.

Esperion Stock Institutional Investors

The Esperion Therapeutics' institutional investors refer to entities that pool money to purchase Esperion Therapeutics' securities or originate loans. These institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds.
Shares
Two Sigma Advisers, Llc2024-06-30
3.9 M
Meditor Group Ltd2024-09-30
3.8 M
State Street Corp2024-06-30
3.8 M
Two Sigma Investments Llc2024-09-30
3.6 M
Centerbook Partners Lp2024-09-30
3.1 M
Whitefort Capital Management, Lp.2024-06-30
2.3 M
Nuveen Asset Management, Llc2024-06-30
2.3 M
Jpmorgan Chase & Co2024-06-30
M
Rhenman Partners Asset Management Ab2024-09-30
M
Wasatch Advisors Lp2024-09-30
23.3 M
Blackrock Inc2024-06-30
14 M
Note, although Esperion Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Esperion Therapeutics Greeks

Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Esperion Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Esperion Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Esperion stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α
Alpha over Dow Jones
0.46
β
Beta against Dow Jones1.96
σ
Overall volatility
4.61
Ir
Information ratio 0.13

Esperion Therapeutics Volatility Alert

Esperion Therapeutics shows above-average downside volatility for the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Esperion Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Esperion Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.

Esperion Therapeutics Fundamentals Vs Peers

Comparing Esperion Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Esperion Therapeutics' direct or indirect competition across all of the common fundamentals between Esperion Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Esperion Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Esperion Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Esperion Therapeutics by comparing valuation metrics with those of similar companies.
    
 Better Than Average     
    
 Worse Than Average Compare Esperion Therapeutics to competition
FundamentalsEsperion TherapeuticsPeer Average
Return On Equity-2.61-0.31
Return On Asset0.0384-0.14
Profit Margin(0.29) %(1.27) %
Operating Margin(0.31) %(5.51) %
Current Valuation630.63 M16.62 B
Shares Outstanding197.04 M571.82 M
Shares Owned By Insiders0.49 %10.09 %
Shares Owned By Institutions66.33 %39.21 %
Number Of Shares Shorted31.25 M4.71 M
Price To Earning(8.19) X28.72 X
Price To Book98.42 X9.51 X
Price To Sales1.69 X11.42 X
Revenue116.33 M9.43 B
Gross Profit(70.42 M)27.38 B
EBITDA(150.11 M)3.9 B
Net Income(209.25 M)570.98 M
Cash And Equivalents185.84 M2.7 B
Cash Per Share2.79 X5.01 X
Total Debt540.95 M5.32 B
Current Ratio3.07 X2.16 X
Book Value Per Share(1.89) X1.93 K
Cash Flow From Operations(135.49 M)971.22 M
Short Ratio6.99 X4.00 X
Earnings Per Share(0.67) X3.12 X
Price To Earnings To Growth(4.78) X4.89 X
Target Price7.51
Number Of Employees24018.84 K
Beta0.95-0.15
Market Capitalization500.47 M19.03 B
Total Asset205.8 M29.47 B
Retained Earnings(1.55 B)9.33 B
Working Capital44.84 M1.48 B
Current Asset214.39 M9.34 B
Note: Disposition of 197 shares by Warren Eric of Esperion Therapeutics at 2.165 subject to Rule 16b-3 [view details]

Esperion Therapeutics Market Momentum

Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Esperion . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.

About Esperion Therapeutics Buy or Sell Advice

When is the right time to buy or sell Esperion Therapeutics? Buying financial instruments such as Esperion Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.

Use Investing Ideas to Build Portfolios

In addition to having Esperion Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Aggressive Funds Thematic Idea Now

Aggressive Funds
Aggressive Funds Theme
Funds or Etfs that attempt to achieve high capital gains by investing in companies with high growth potential and above average risk. The Aggressive Funds theme has 48 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Aggressive Funds Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Esperion Stock Analysis

When running Esperion Therapeutics' price analysis, check to measure Esperion Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Esperion Therapeutics is operating at the current time. Most of Esperion Therapeutics' value examination focuses on studying past and present price action to predict the probability of Esperion Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Esperion Therapeutics' price. Additionally, you may evaluate how the addition of Esperion Therapeutics to your portfolios can decrease your overall portfolio volatility.